Retigabine filings completed in the US and Europe

Meda’s partner for Retigabine, Valeant Pharmaceuticals, today announced that Retigabine completed both the New Drug Application (NDA) and the Marketing Authorisation Application (MAA) submissions on October 30, 2009. Retigabine comprises a new way of affecting potassium channels in the central nervous system. It has been documented to treat epilepsy and has a different mechanism of action compared to current antiepileptic therapies. The pharmaceutical company GlaxoSmithKline has signed a worldwide collaboration agreement with Valeant Pharmaceuticals for the Retigabine substance. Meda is entitled to receive significant royalties and certain milestone payments on the Retigabine substance.

---